Physician profile
James Harb
NPI 1316435522
$10,520.22
in general payments reported to CMS, 2019-2025
44 companies · $3,172 in 2025
The $3,172 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,485 · 2023: $2,738 · 2024: $3,125 · 2025: $3,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,890 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,889.97 |
| Education | $145.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,031.91 | 2022-2025 | |
| Pfizer INC. | $893.79 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $867.35 | 2022-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Collegium Pharmaceutical, INC. | $771.95 | 2022-2025 | Xtampza, Belbuca |
| Tonix Medicines, INC. | $623.69 | 2024-2025 | Zembrace Symtouch |
| Lundbeck LLC | $548.61 | 2022-2025 | Vyepti, Rexulti |
| Jazz Pharmaceuticals INC. | $487.25 | 2023-2025 | |
| Sk Life Science, INC. | $372.95 | 2022-2025 | |
| Axsome Therapeutics, INC. | $357.88 | 2023-2025 | Sunosi, Symbravo |
| Amgen INC. | $334.43 | 2022-2023 | Aimovig |
| Biohaven Pharmaceutical Holding Company LTD. | $322.38 | 2022 | |
| Ucb, INC. | $304.40 | 2023-2025 | Nayzilam, Briviact, Fintepla |
| Lilly USA, LLC | $296.89 | 2022-2023 | Emgality, Reyvow |
| Impel Pharmaceuticals INC. | $285.82 | 2023 | Trudhesa |
| Upsher-Smith Laboratories LLC | $245.56 | 2022-2023 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $224.68 | 2023-2025 | Ztlido |
| Averitas Pharma INC. | $194.88 | 2023-2025 | Qutenza |
| Neurocrine Biosciences, INC. | $133.48 | 2023-2025 | Ingrezza, Ongentys |
| Impel Pharmaceuticals LLC | $108.21 | 2024-2025 | Trudhesa |
| Azurity Pharmaceuticals, INC. | $106.56 | 2023-2024 | Horizant, Horizant, Gliadel |
| Catalyst Pharmaceuticals, INC. | $95.26 | 2023-2025 | Fycompa |
| Vertex Pharmaceuticals Incorporated | $87.40 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $83.10 | 2022-2023 | Onzetra Xsail, Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.94 | 2024-2025 | Relistor |
| Eisai INC. | $73.40 | 2025 | |
| Amneal Pharmaceuticals LLC | $69.36 | 2023-2025 | Brekiya, Rytary, Avastin |
| Csl Behring | $60.28 | 2024 | Hizentra |
| Ipsen Biopharmaceuticals, INC | $59.14 | 2025 | Dysport |
| Harmony Biosciences LLC | $51.66 | 2023-2024 | Wakix |
| Ibsa Pharma INC. | $50.22 | 2024-2025 | Licart, Tirosint, Flector |
| Alnylam Pharmaceuticals INC. | $48.10 | 2024-2025 | Onpattro |
| Kyowa Kirin, INC. | $26.51 | 2023 | Nourianz |
| Merz Pharmaceuticals, LLC | $25.19 | 2023 | Xeomin |
| Boston Scientific Corporation | $24.66 | 2023 | |
| Corium, LLC | $24.55 | 2023 | Adlarity |
| Novo Nordisk INC | $24.16 | 2025 | Wegovy |
| Tersera Therapeutics LLC | $21.85 | 2023 | Prialt |
| Alexion Pharmaceuticals, INC. | $20.34 | 2022 | |
| Novocure INC. | $19.49 | 2023 | Optune |
| Gilead Sciences, INC. | $18.19 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $17.97 | 2023 | Nuedexta |
| Supernus Pharmaceuticals, INC. | $16.65 | 2022 | |
| Banner Life Sciences, LLC | $15.13 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$310,343.55 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Harb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.